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AbstrAct:
CD277, a member of the butyrophilin subfamily 3 (BTN3), shares significant sequence 
similarities and predicted common structural features with inhibitory B7-H4 and other 
members of the B7 superfamily. Here we report that CD277 is consistently expressed 
in stromal, as well as tumor cells in the microenvironment of human advanced ovarian 
carcinoma specimens, both of primary and metastatic origin. MHC-II+ myeloid antigen-
presenting leukocytes (dendritic cells and macrophages) express significantly 
higher levels of surface CD277, compared to other tumor-infiltrating leukocyte 
subsets, and this expression is significantly up-regulated by multiple common tumor 
microenvironmental signals, including VEGF and CCL3. Most importantly, engagement 
of CD277 on the surface of TCR-stimulated T cells inhibits their otherwise robust 
expansion and production of Th1 cytokines by preventing the up-regulation of cFLIP. 
Our results point to a role for CD277 up-regulated by microenvironmental 
signals in the acquisition of a regulatory phenotype by tumor-associated myeloid 
cells. Consequently, CD277, and likely other butyrophilins and butyrophilin-like 
molecules, emerge as regular players in the orchestration of immunosuppressive 
networks in ovarian cancer, and therefore new targets for interventions to 
overcome immune evasion and boost anti-tumor immunity in cancer patients.
Abbreviations used:  aAPC, artificial Antigen-Presenting Cell; BTN, Butyrophilin; MDSC, Myeloid-Derived Supressor Cell, VLC, 
Vascular Leukocyte; DC, Dendritic Cell; VEGF, Vascular Endothelial Growth Factor A; PlGF, Placental Growth Factor; CCL3, C-C 
motif chemokine 3.
INtrODUctION
Despite being an underfunded disease, epithelial 
ovarian cancer is responsible for the death of ~15,000 
Americans per year, even more than melanoma or brain 
tumors[1]. Five-year survival rates have improved little 
in the last 30 years, and still remain at 30%, at best, for 
patients with metastatic ovarian carcinoma, the stage 
at which most cases are diagnosed[1, 2]. The standard 
course of treatment for ovarian cancer, surgical debulking 
followed by chemotherapy, usually eliminates detectable 
tumors and puts the cancer into remission. Unfortunately, 
most patients relapse within 2 years and the tumors that 
then develop are commonly resistant to chemotherapy 
and are frequently fatal. We and others have demonstrated 
that in the ovarian carcinoma microenvironment only T 
cells can spontaneously exert clinically relevant pressure 
against tumor progression. Simply defining the location 
where tumor-infiltrating T lymphocytes accumulate 
predicts the patient’s outcome[3-7]. However, as 
the dismal statistics show, spontaneously developed 
antitumor immunity is too often insufficient. In part, this 
is because many cancers, including ovarian cancer[8-15], 
suppress the antitumor immune response by expressing 
molecules that induce immune tolerance to the tumor 
by recruiting immunosuppressive stromal leukocytes in 
the tumor microenvironment (as elegantly reviewed by 
W. Zou[14]). One area of great potential is stimulating 
antitumor immunity, but immunological understanding 
of the epithelial ovarian cancer tumor microenvironment 
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is limited[8-10, 16-18], and tumor-induced 
immunosuppression has so far impeded the development 
of improved immunotherapies. The particularly 
immunosuppressive nature of the ovarian carcinoma 
microenvironment has even abrogated the effectiveness of 
the most promising strategies based on stimulating T cell-
mediated immune responses through adoptive transfer[10, 
16, 19]. A better understanding of the peculiarities of 
this particularly abrasive microenvironment is therefore 
urgently required.
Engagement of co-inhibitory molecules plays a 
crucial role in the abrogation of T cell responses in the 
context of cancer and chronic infections[20]. Signals 
mediated by members of the B7 family of molecules, 
including PD-L1 and B7-H4, appear to be crucial for the 
orchestration of an immunosuppressive microenvironment 
in cancer patients in general[15, 21, 22], and both are 
abundantly expressed in ovarian tumors in particular[12, 
15, 22, 23]. 
Interestingly, butyrophilin (BTNs) and butyrophilin-
like molecules share significant sequence homology 
with B7 family members, but little is known about their 
functions in specific biological contexts. BTNs are 
transmembrane proteins belonging to the Ig superfamily 
that can be divided into three groups, termed BTN1, 
BTN2 and BTN3. 
Emerging results indicate that some BTN1 and 
BTN2 molecules could play a role in the impairment of 
T cell responses[24]. In addition, BTNL2, a BTN/B7-like 
molecule has been identified as a negative co-stimulatory 
molecule modulated in intestinal inflammation and also 
associated with sarcoidosis[25-27]. However, little 
is known regarding the potential of BTN3 subfamily 
members as immunosuppressive ligands. The role of 
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Figure 1: cD277 shares sequence and structural similarity with other members of the b7 superfamily of costimulatory 
molecules. (A) Alignment of CD277 and B7-H4. Conserved cysteine residues are highlighted in red. Conserved Amino Acid regions are 
highlighted in black. (B) Cluster analysis of B7 superfamily members. The Amino Acid sequence of CD277 was aligned to other B7 superfamily 
members and a similarity tree was generated. (C) (left and center) Presentation of the CD277 and B7-H4 structures, predicted using the know 
structure of PD-L1 as a model, based on sequence. (right) Schematic overlay of both predicted structures. Blue, CD277; Orange, B7-H4.
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BTNs in the modulation of spontaneous anti-tumor 
immune responses has never been investigated, despite 
the fact that BTNs are expressed on a variety of immune 
cells and tumor cell lines in a pattern identical to that of 
co-inhibitory molecules of the B7 family, and could thus 
play a similar tolerogenic role[28]. 
Here we report that CD277, a member of the 
butyrophilin subfamily 3 (BTN3), is universally 
expressed by myeloid APCs and tumor cells in the human 
ovarian carcinoma microenvironment and inhibits the 
TCR-mediated expansion of human T cells as well as the 
production of Th1 cytokines. Our results point to CD277 
as a new target for the design of novel interventions to 
overcome immune evasion and boost anti-tumor immunity 
in ovarian cancer patients.
rEsULts
CD277 shares significant sequence similarities 
and common structural features with inhibitory 
b7-H4
B7-H4 plays a crucial role in the orchestration of 
immune evasion in the microenvironment of human 
ovarian carcinomas, where it is primarily expressed on 
the surface of tumor-associated macrophages and tumor 
cells, and interacts with an unidentified receptor in T 
cells[15, 22]. We identified that the extracellular domain 
of CD277/BTN3A1, a type I transmembrane member of 
the butyrophilin family, shows a striking similarity with 
the extracellular domain of immunosuppressive B7-H4, 
with 26% identities including a conserved pattern of 4 
cysteins in identical positions (Figure 1A). Similar to B7-
H4, CD277 is expressed on leukocytes including antigen-
presenting cells[28]. Although CD277 shows a high degree 
of resemblance with other members of the B7 superfamily 
(not shown), it clusters more closely with B7-H4 when a 
Figure 2: cD277 inhibits tcr-mediated human t cell proliferation. (A) FACS analysis of CD277 expression by mock-transduced 
K32 (aAPCs) cells (solid) and K32 cells stably infected with a retroviral construct encoding CD277 (open). (B) Untransduced or CD277-
expressing K32 cells were loaded with anti-CD3 agonistic antibodies (OKT3; 100 ng/ml) and cells were then co-cultured (1:10) with CFSE-
labeled human peripheral blood T cells. The percentage of proliferating T cells was analyzed by FACS after five days of proliferation. Data 
are representative of five independent experiments with similar results. (C) Representative FACS analysis of the data shown in B. **P<0.05 
(Mann-Whitney). (D) CD28 costimulation alleviates CD277-mediated suppression. K32 cells were loaded with anti-CD3 and anti-CD28 
agonistic antibodies (25 ng) and cells were cocultured with human T cells, as described above. CFSE dilution was evaluated by FACS five days 
later. Data are representative of four independent experiments with similar results
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similarity tree is generated based on amino acid sequence 
alignment (Figure 1B). Correspondingly, the predicted 
three-dimensional structure of the extracellular domains 
of both molecules revealed multiple common features and 
the presence of a similar overall tertiary structure (Figure 
1C). 
cD277 inhibits the tcr-mediated proliferation 
of activated human t cells
Based on the sequence and structural similarity of 
CD277 and B7-H4, we hypothesized that CD277 could also 
act as a negative co-stimulatory molecule that regulates T 
cell activation. To define the effect of increased CD277 
availability on T cell proliferation, we used an established 
system to induce the expansion of human T cells based 
on artificial antigen-presenting cells (aAPCs)[29, 30]. 
Briefly, K562 cells, which lack MHC-I expression, were 
transduced with CD32 to generate K32 cells. K32 cells 
were irradiated, coated with different concentrations of 
activating CD3 and CD28 antibodies and incubated with 
naïve T cells, to induce rapid proliferation. We transduced 
these aAPCs with the open-reading frame of CD277 
(NM_007048) and confirmed the presence of the protein 
on their surface by FACS analysis (Figure 2A). 
As shown in Figure 2B, the TCR-induced 
proliferation of naïve human T cells was significantly 
impaired when CD77 was expressed on aAPCs in 
5 independent experiments (30% decrease in total 
proliferating cells, Figure 2C; 78 % decrease in the 
division index, not shown). Of note, impairing the strong 
proliferative activity elicited by optimal concentrations 
of agonistic anti-CD3 antibodies (100 ng/ml) on human 
T cells, implies a profound inhibitory effect. Importantly, 
the immunosuppressive effect of CD277 could be 
alleviated, but not completely restored, in the presence 
of CD28 co-stimulation (Figure 2D). In contrast, K32 
aAPCs transduced with the leukocyte ligand PILAR[30] 
dramatically enhanced T cell proliferation under identical 
experimental conditions (data not shown). 
Most importantly, the regulatory effect of CD277 
appears to be mediated by a receptor selectively expressed 
on the surface of activated T cells, because only CD3/
CD28-stimulated, but not naïve T cells, bound to a Myc-
tagged recombinant extracellular domain of CD277 
(Figure 3A).
Together, these data suggest that CD277, similar to 
various members of the B7 superfamily of co-inhibitory 
molecules, plays a role in fine tuning of antigen-specific 
responses by binding to an inhibitory receptor expressed 
on the surface of activated T cells. These results also 
suggest that CD277 may participate in the balance between 
activation and inhibition during T cell homeostasis.
cD277 inhibits cytokine secretion and c-Flip 
expression by human t cells
TCR-mediated activation of T cells results in 
increased expression of cellular caspase-8 (FLICE)-like 
inhibitory protein (cFLIP), which augments caspase-8 
activity, necessary to initiate the activation of nuclear 
factor-B (NF-B) and promote T cell proliferation[31]. We 
therefore compared cFLIP expression on T cells stimulated 
with agonistic CD3 antibodies in the presence or the 
absence of CD277. As shown in Figure 3B, increasing 
CD277 availability completely abrogated the expression of 
c-FLIP after 24 h of stimulation. Interestingly, impairment 
of T cell expansion by CD277 expression was not caused 
by a direct apoptotic effect, because intracellular staining 
of Annexin V produced identical signals in T cells 
expanded in the presence or the absence of ectopic CD277 
in multiple experiments (Figure 3C). 
Importantly, CD277 over-expression profoundly 
decreased the production of Th1 cytokines IL-2 and INF-g 
by stimulated T cells, although the production of TNF-a 
was only slightly affected on a per cell basis (Figure 4). 
In contrast, IL-17 and, especially, IL-6 production was 
enhanced in the presence of CD277.
Figure 3: cD277 inhibits cFLIP in activated human 
t cells. (A) Resting human T cells or T cells activated for 24 
hours with anti-CD3/anti-CD28 beads were incubated with a 
Myc-tagged irrelevant protein or a with Myc-tagged extracellular 
form of CD277. Protein binding to the cell surface was analyzed 
by FACS using a secondary anti-Myc antibody. Data are 
representative of three independent experiments with similar 
results. iProt, irrelevant protein. eCD277, extracellular region of 
CD277. (B) Human T cells were cocultured for 24 hours with 
K32 cells ectopically expressing or not CD277 and whole cell 
lysates were used to analyze c-Flip expression by Western blot. 
Data are representative of two independent experiments with 
similar results. (C) Resting human T cells were activated for 
24 hours with K32 cells ectopically expressing (solid) or not 
(open) CD277 and intracellular expression of Annexin V was 
determined. 
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Together, these data indicate that CD277 impairs 
the expansion of TCR-stimulated T cells by preventing 
the up-regulation of cFLIP, which results in a dramatic 
decrease in Th1 cytokine production. 
cD277 is abundantly expressed in all advanced 
human ovarian carcinoma specimens analyzed
Having demonstrated that CD277 acts as a negative 
signal to modulate T cell proliferation we hypothesized 
that, similar to structurally related B7-H4, CD277 
could also play a role in immune evasion in the ovarian 
carcinoma microenvironment. To test this hypothesis, 
we first confirmed that 12 unselected stage III/IV human 
ovarian carcinoma solid specimens from our tumor bank 
expressed significant mRNA levels of CD277 (Figure 5A). 
Comparable levels of inhibitory CD277 were detected in 
samples from the primary tumor (n=6) and metastatic 
masses (n=6). In addition, 3 out of 3 established ovarian 
cancer cell lines analyzed also express detectable CD277 
(Figure 5A). Correspondingly, immunohistochemical 
analysis of 30 tumor specimens from patients with 
epithelial ovarian carcinoma (including both metastatic 
and primary masses) revealed that all specimens analyzed 
were strongly positive for CD277 protein (Figure 5B), 
while no positive signal was detected with the isotype 
control antibody. CD277 signal was found in abundant 
cells in the stroma as well as tumor islets (Figure 5B, 
left). In several histological sections, a layer of non-
tumor CD277+ cells distributed in a vascular-like pattern 
was found around tumor islets (Figure 5B, right). No 
differences between primary vs. metastatic specimens 
were noted.
These data suggest that inhibition of T cell-mediated 
anti-tumor immune responses by immunosuppressive 
CD277 may be a common mechanism of evasion 
orchestrated by stromal and tumor cells in the 
microenvironment of advanced human epithelial ovarian 
cancers. 
cD277 is expressed by human ovarian cancer 
microenvironmental antigen-presenting cells
To define the precise cell types expressing 
immunosuppressive CD277 in the human ovarian 
carcinoma microenvironment, we mechanically 
dissociated 7 randomly received fresh stage III/IV epithelial 
ovarian cancer samples, which included 2 primary and 
5 metastatic specimens. FACS analysis of these freshly 
prepared single cell suspensions revealed that CD277 was 
most highly expressed on the surface of CD45+ MHC-
II+ leukocytes in all samples (Figure 5C). Although the 
precise categorization of these leukocytes is complicated 
by the fact that they co-express other macrophage and 
myeloid-derived suppressor cell (MDSC) markers, we 
have previously demonstrated that in the solid tumor 
microenvironment in humans most of these leukocytes 
express low but detectable levels of phenotypic markers 
of immature but bona fide dendritic cells (DCs), including 
CD11c, DEC205 and CD86, and are negative for CD20 
and therefore not B cells[8-10, 13, 18]. We initially termed 
these cells as Vascular Leukocytes (VLCs) because they 
up-regulate endothelial markers at perivascular locations 
in tumors. Thus, the distribution of CD277+ structures 
around tumor islets found in some specimens is consistent 
with the perivascular homing of VLCs in ovarian 
cancer[32, 33]. In addition, CD45+MHC-II+ leukocytes 
in tumor ascites (primarily canonical macrophages in our 
hands) also expressed significant levels of surface CD277 
(Figure 5C).
Expression of CD277 in tumor-associated MHC-II+ 
DC/macrophages was significantly higher than that in other 
ovarian cancer microenvironmental leukocyte subsets in 
most specimens analyzed, both primary and metastatic 
(Figure 6A). Interestingly, CD3+ T cells infiltrating 
ovarian carcinoma specimens, including regulatory 
T cells (CD3+CD4+CD25+) did not show detectable 
levels of CD277 (Figure 6B). In contrast, variable but 
substantial levels of CD277 were found in CD45- cells 
(Figure 6C) suggesting that, similar to established tumor 
cell lines, ovarian tumor cells also up-regulate CD277 as a 
mechanism of immune evasion.
Figure 4: cD277 inhibits th1 cytokine secretion by tcr-stimulated human t cells. K32 cells expressing or not CD277 were 
loaded with anti-CD3 agonistic antibodies and cells were cocultured with human T cells as described above. Culture supernatants were collected 
after five days and cytokine secretion was analyzed by Multiplex analysis. Data are representative of two independent experiments with similar 
results. **P<0.05 (Mann-Whitney).
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Together, these data indicate that inhibitory CD277 
is consistently up-regulated by abundant stromal and 
tumor cells in the ovarian cancer microenvironment, 
thus pointing to a crucial role for this molecule in the 
orchestration of immunosuppressive networks.
cD277 expression is up-regulated in human 
DCs by inflammatory cytokines and hypoxia-
associated mediators
Because CD277 is over-expressed in tumor 
microenvironmental MHC-II+ DC/macrophages, we 
finally aimed to define microenvironmental factors 
mediating its up-regulation. We therefore generated DCs 
from human aphaeresis samples and incubated them with a 
variety molecules frequently over-expressed in the tumor 
microenvironment, and determined how CD277 levels 
were impacted. As shown in Figure 7, DCs expressed low 
but detectable levels of CD277, which were further up-
regulated upon incubation with tumor-derived ascites or 
inflammatory IL-6. Interestingly, hypoxia-induced VEGF 
and PlGF, commonly up-regulated in most solid tumors, 
induced the highest up-regulation of CD277 in human 
DCs. Among common inflammatory cytokines, incubation 
with CCL3 dramatically increased the expression of 
CD277 too. CCL3 is, interestingly, produced at high levels 
by tumor-associated DCs (unpublished observations), 
and therefore abundantly over-produced in the tumor 
microenvironment.
Together, these data indicate that multiple common 
tumor microenvironmental signals induce the up-
regulation of CD277 in tumor-associated APCs, thus 
stimulating their acquisition of a regulatory phenotype.
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II+CD20- (solid), compared to that of other CD45+ cells (open) 
within the same human specimens. (B) FACS analysis of CD277 on 
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in a metastatic ovarian cancer tumor. Solid histograms indicate CD277 
expression, open histograms represent isotype control staining. 
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analyzed for CD277 expression on T cells. (C) Representative FACS 
analysis of CD277 expression on CD45- cells in dissociated ovarian 
cancer specimens (mainly tumor cells; open thicked), compared to 
that in CD45+MHC-II+CD20- inflammatory leukocytes (solid) in the 
same specimen. Open dashed histograms represent isotype control 
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Figure 5: cD277 is abundantly expressed in the 
microenvironment of human epithelial ovarian cancer. 
(A) Real Time RT-PCR analysis of CD277 mRNA levels in human 
ovarian cancer cells lines (SKOV3, Ovcar60 and A2008) and multiple 
human tumor specimens. (B) Representative immunohistochemistry 
of CD277 protein expression in ovarian tumors from two different 
patients (magnification, x200). (C) Single-cell suspensions from 
different stage III-IV human ovarian tumors and ascites were procured 
and surface expression of CD277 on CD45+MHC-II+ leukocytes 
(CD20-)[13] was determined by FACS. Open histograms represent 
staining with isotype control antibodies, solid histograms indicate 
CD277 staining. 
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Positive and negative co-stimulatory molecules 
cooperatively determine the activation of T cells[34]. 
A growing body of evidence indicates that multiple 
negative co-stimulatory molecules expressed by tumor 
and tumor microenvironmental cells are crucial to confer 
immune privilege against T cell-mediated eradication. 
Here we show that CD277, a member of the BTN family, 
inactivates T cell function and is consistently expressed 
by ovarian cancer-associated MHC-II+ DC/macrophages 
leukocytes as well as primary ovarian cancer cells in all 
specimens analyzed. 
CD277 shares significant sequence identities and 
common structural attributes with inhibitory B7-H4. 
Similar to B7-H4 and also to other members of the B7 
superfamily of co-inhibitory molecules such as PD-
L1, CD277 impairs TCR-induced proliferation and Th1 
cytokine production by human T cells. These inhibitory 
effects are associated with a blockade in the up-regulation 
of cFLIP, necessary to promote T cell proliferation[31]. 
Although impairment of T cell activation by other 
members of related sub-families of BTNs[24], or BTN-
like molecules[25, 26], has been recently proposed, the 
role of CD277, or any other member of the BTN3 sub-
family as a ligand, remained completely unknown. 
During the preparation of this manuscript, a report 
showing the effect of signaling directly through BTN3 in 
lymphocytes was published online[35]. The presence of 
CD277 on the surface of T cells has been confirmed by 
others[28], although our results indicate that in the ovarian 
microenvironment, little to no expression of CD277 can be 
detected on the surface of tumor-infiltrating lymphocytes, 
including regulatory T cells, using commercial antibodies. 
In contrast, we found that CD277 is significantly expressed 
in myeloid MHC-II+ leukocytes (primarily DCs, in our 
hands[8-10, 13, 18]) and tumor cells. Therefore, the 
inhibition of the anti-tumor function of T cells at tumor 
locations should be mediated by the engagement of 
CD277 expressed on APCs or tumor cells with another 
receptor expressed in T cells. In fact we confirmed that 
CD277 selectively binds to the surface of activated, but 
not resting T cells, indicating that the inhibitory activity 
of CD277 depends on the stimulation of a receptor that is 
expressed during T cell activation. Due to the structurally 
similar features of CD277 and PD-L1 (not shown), we 
surmised that PD-1, which is up-regulated in T cells upon 
activation, could mediate the observed non-apoptotic 
regulatory effects. However, PD-1 has been previously 
ruled out as a binding partner of CD277 by others[28], 
and we were not able to generate conclusive evidence 
for CD277:PD-1 interactions. The receptor for CD277, 
similar to the receptor for other BTNs or B7-H4, therefore 
remains to be identified. 
Also similar to B7-H4 and PD-L1, CD277 is 
expressed by both leukocytes and non-hematopoietic 
tumor cells, suggesting that it may impair T cell function 
at the tissue level, beyond the lymph node where T cell 
priming takes place. Correspondingly, we found that 
CD277 is consistently expressed in all human advanced 
ovarian carcinoma specimens analyzed, and comparable 
levels and patterns of expression were found in metastatic 
and advanced (stage III/IV) primary tumor specimens. 
Indeed, we found that CD277 is up-regulated in monocyte-
derived DCs by multiple inflammatory cytokines and 
hypoxia-induced mediators commonly found in the tumor 
microenvironment, including VEGF, and CCL3 and, to 
a lesser extent, IL-6. Our data indicate that both CCL3 
and IL-6 are produced at high levels by tumor-associated 
DCs (not shown), which is supported by independent 
reports[36]. These results therefore point to a scenario in 
which ovarian cancer cells as well as tumor-infiltrating 
leukocytes secrete multiple factors that induce the 
expression of CD277 on infiltrating APCs, which would 
impair the function of tumor-reactive T cells. As we have 
published, multiple immunosuppressive mechanisms are 
orchestrated by the abundant regulatory DC population 
found in solid ovarian tumors[8, 13, 16-18]. The inhibition 
of T cell-mediated anti-tumor immune responses by 
immunosuppressive CD277 may be therefore a common 
mechanism of immune evasion in ovarian cancer patients, 
and perhaps in other tumors.  Importantly, the 
extracellular domain of BTN3A3 shares 97% sequence 
identity with CD277, suggesting identical inhibitory 
functions. In addition, given the redundant activities 
of other BTNs from different sub-families, multiple 
BTNs could converge in the tumor microenvironment to 
inhibit anti-tumor adaptive immune responses and create 
immune privilege. BTNs can therefore be essential for 
understanding potential immune evasion in cancer and 
represent crucial immunotherapeutic targets.
MEtHODs
Figure 7: Tumor microenvironmental inflammatory 
cytokines and hypoxia-associated mediators up-regulate 
the expression of cD277 in monocyte-derived human 
Dcs. Monocyte-derived DCs were incubated for 18 hours with the 
indicated cytokines and CD277 expression was evaluated by Real 
Time Quantitative PCR. 
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Ethics statement
Investigation has been conducted in accordance with 
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of Helsinki and according to national and international 
guidelines and has been approved by the author’s 
institutional review board.
tissues, cell lines and treatments
Stage III/IV human ovarian cancer tissues (n=30) 
were obtained through Research Pathology at Dartmouth 
Medical School, Lebanon, NH, after institutional 
approval. Single-cell suspensions were generated by 
gently forcing minced fresh specimens through a 70-μm 
pore mesh and subjected to Ficoll gradient centrifugation. 
Human ovarian cancer cell lines SKOV3, Ovcar60 and 
A2008 were grown to 80% confluency in DMEM medium 
containing 10% FBS prior to RNA isolation.
Peripheral blood lymphocytes were obtained by 
leukapheresis/elutriation and Miltenyi bead–purified, as 
described[5]. 
Monocyte-derived dendritic cells (MoDCs) were 
generated by incubating magnetically purified CD14+ 
cells for 7 days with granulocyte-macrophage colony 
stimulating factor (20 ng/mL; PeproTech,) and IL-4 (50 
ng/mL; R&D Systems). MoDCs were then stimulated for 
3 days with IL-10 (200 ng/ml), IL-6 (10 ng/ml), CCL3 (50 
ng/ml), VEGF (50 ng/ml), PLGF-1 (50 ng/ml) or filter-
sterilized human ovarian cancer ascites at a 1:1 ratio. 
Immunohistochemistry was performed using 
a purified anti-CD277 antibody (clone eBioBT3.1, 
eBioscience) and the ABC kit (Chemicon International, 
Temecula, CA), as reported[3, 13, 18]. Horse serum (1/10 
dilution) was used as a negative control. 
Artificial antigen presenting cells (K32) were 
generated by stably expressing human CD32 on the 
surface of K562 cells, as previously described[29, 30]. 
CD277 was PCR amplified from human spleen cDNA 
using primers BTN-Fw (5’ GTT GGG ACT CAA AGG 
TGA AGA C 3’) and BTN-Rev (5’ TGT CTC TAG GGA 
ATG ATC AGC A 3’). Expression of CD277 on K32 cells 
was achieved using the MSCV Retroviral Expression 
System (Clontech), following the recommendations of the 
manufacturer. 
For T cell proliferation experiments, K32 cells 
expressing or not CD277 were γ-irradiated (100 Gy), 
washed twice with 1X PBS, and loaded with anti-CD3 
alone (100 ng/ml, clone OKT3; eBioscience) or anti-
CD3 (25 ng/ml) plus anti-CD28 (100 ng/ml, clone 15E8; 
Chemicon International) antibodies at room temperature 
for 10 min. T cells were CFSE-labeled and cocultured 
with loaded K32 cells at a 10:1 ratio. Proliferation of 
stimulated T cells was determined 5 days later by FACS 
on the basis of CFSE dilution.
rNA isolation, cDNA generation and real time 
Pcr
In all cases, total RNA was extracted using Trizol 
(Invitrogen) and total cDNA was generated using 
SuperScript III Reverse Transcriptase (Invitrogen) and 
random primers, following the recommendations of the 
manufacturer. CD277 mRNA levels were quantified 
by Real Time PCR using TaqMan assays (Applied 
Biosystems) and primers qBTN-F (5’ GGA GGG TGT 
ATC CTG TAC CAT CA 3’), qBTN-R (5’ AAG AAG 
CAG CAG CAA GAC AGG 3’) and the internal probe 
pBTN (5’ CCT GGA AAA GAC AGC CAG CAT 3’). In 
all experiments CD277 expression was normalized among 
samples by quantifying the messenger levels of GAPDH 
using primers GAPDH-F (5’ CCT GCA CCA CCA ACT 
GCT TA 3’), GAPDH-R (5’ AGT GAT GGC ATG GAC 
TGT GGT 3’) and the internal probe pGAPDH (5’ CCT 
GGC CAA GGT CAT CCA TGA CAA C 3’) 
Flow cytometry, bio-Plex and Immunoblotting
Flow cytometry was performed on a FACSCanto 
(BD Biosciences, San Jose, CA). Cell populations were 
sorted from human tumor single-cell suspensions using a 
FACSAria sorter (BD Biosciences). Anti-human antibodies 
were specific for CD45 (HI30), DEC205 (MG38), CD3 
(UCHT1), CD4 (OKT4), CD11b (ICRF44), CD14 
(M5E2) all from BD Biosciences; CD277 (20.1, BT3.1) 
and CD25 (BC96) antibodies were from eBioscience. 
Cytokines in supernatants from stimulated T cells 
were quantified in a Bio-Plex assay (Bio-Rad, Hercules, 
CA) using the Human-27-Plex panel. Plates were read in 
a Bio-Plex Array Reader (Bio-Rad). 
Intracellular expression of Annexin V was determined 
using the Annexin V-FITC Apoptosis Detection Kit (BD 
Biosciences), following manufacturer’s instructions.
To determine c-Flip expression, pellets from CD277-
exposed T cells were resuspended in 30 μl Laemmli buffer, 
boiled for 5 min, loaded onto a 15% sodium dodecyl 
sulfate–polyacrylamide electrophoresis gel, transferred to 
a nitrocellulose membrane, blocked, and incubated with 
an anti-human c-Flip antibody (C-terminus; eBioscence). 
Immunoreactive bands were developed using horseradish 
peroxidase–conjugated secondary antibodies (Bio-Rad) 
and chemiluminescent substrates (Pierce Chemical, 
Rockford, IL). In all cases, membranes were re-probed 
with an anti-GAPDH antibody (BioLegend) as loading 
control. 
soluble proteins and binding assays
The extracellular portion of BTN3A1 (aa 30-254) 
was PCR amplified from human spleen cDNA using 
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primers eBTN-F (5’ aag ctt CAG TTT TC TGT GCT TGG 
AC 3’) and eBTN-R (5’ gaa ttc TCT GGG CGC TCC TGA 
AGA AG 3’), wherein the lower case nucleotides represent 
HindIII and EcoRI sites, respectively. The amplified 
product was subcloned in frame into the expression vector 
pSecTag2B (Invitrogen) following the recommendations of 
the manufacturer, to generate a secreted protein containing 
the BTN3A1 extracelullar portion fused to a C-terminal 
Myc epitope and a poly-histidine tag. HEK293 cells were 
transfected with the resulting vector and secreted CD277 
was purified from culture supernatants 3 days later using 
the His GraviTrap system (GE Healthcare). To generate a 
control extracelullar protein (iProt), HEK293 cells were 
transfected with empty pSecTag2B, which generates an 
irrelevant His-tagged polypeptide containing a C-terminal 
Myc epitope. For binding assays, resting or CD3/CD28 
bead-activated T cells were incubated with the tagged 
proteins (0.5 ug/ml) at room temperature for 30 min. Cells 
were washed stringently and protein binding was assessed 
by secondary incubation with a FITC-labeled anti-Myc 
antibody (9E10; Sigma), followed by FACS analysis. 
Prediction of structure and statistical analysis
The structure of the extracellular domains of B7-
H4 and CD277 were modeled using PD-L1 with Protein 
Homology/analog Y Recognition Engine (Phyre)[37]. 
Predicted structures were overlapped using Rasmol 
(http://rasmol.org). Phylogenetic analysis of members of 
the B7 family was performed with ClustalW[38].
Differences between the means of experimental 
groups were analyzed with the Mann-Whitney test using 
the GraphPad Prism 4.0 software.
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